Comparative Pharmacology
Head-to-head clinical analysis: BETOPTIC S versus PINDOLOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETOPTIC S versus PINDOLOL.
BETOPTIC S vs PINDOLOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betaxolol is a cardioselective beta-1 adrenergic receptor antagonist. In ophthalmic use, it reduces intraocular pressure by decreasing the production of aqueous humor, likely through blockade of beta-2 receptors in the ciliary epithelium.
Pindolol is a nonselective beta-adrenergic receptor antagonist with intrinsic sympathomimetic activity (ISA). It blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Its ISA partially stimulates beta receptors, leading to less bradycardia and bronchoconstriction than other nonselective beta-blockers.
Instill 1 drop in the affected eye(s) twice daily.
5 mg orally twice daily, titrated to 10-60 mg/day in divided doses; maximum 60 mg/day.
None Documented
None Documented
Clinical Note
moderateBopindolol + Digoxin
"Bopindolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateBopindolol + Digitoxin
"Bopindolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderatePindolol + Digitoxin
"Pindolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateBopindolol + Deslanoside
"Bopindolol may increase the bradycardic activities of Deslanoside."
Terminal elimination half-life is approximately 4–6 hours in adults; prolonged in renal impairment and in elderly patients due to decreased clearance.
The terminal elimination half-life of pindolol is 3-4 hours. However, due to its intrinsic sympathomimetic activity, the clinical duration of beta-blockade is longer, allowing for once-daily dosing in some patients.
Renal: 0.3% unchanged; extensive hepatic metabolism to inactive metabolites; biliary/fecal elimination of metabolites accounts for the majority of excretion; total renal elimination of drug and metabolites is approximately 80%, with the remainder via feces.
Pindolol is excreted primarily via the kidneys (renal clearance), with 60-65% of the dose eliminated unchanged in urine. Approximately 30-40% is metabolized in the liver, and biliary/fecal excretion accounts for less than 5%.
Category C
Category A/B
Beta-Blocker
Beta-Blocker